Multidrug resistance and its reversal

Area of Science:

• Molecular Biology
• Cancer Research
• Pharmacology

Background:

• Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy, where cancer cells become resistant to structurally and functionally dissimilar cytostatic agents.
• While P-glycoprotein is a well-characterized mediator of MDR, it does not fully explain the phenomenon, necessitating the identification of other contributing factors.
• Emerging research has identified additional genes like MRP and LRP, and the role of topoisomerase II, in conferring MDR.

Purpose of the Study:

• To review and synthesize current knowledge on the mechanisms of multidrug resistance (MDR) in cancer.
• To explore various experimental strategies aimed at reversing MDR, including pharmacological compounds and novel therapeutic approaches.
• To assess the clinical efficacy of MDR reversal agents, particularly in solid tumors versus hematological malignancies.

Main Methods:

• Review of in vitro and in vivo experimental assays investigating MDR reversal strategies.
• Analysis of clinical trial data for agents like verapamil and cyclosporin A in cancer treatment.
• Examination of the role of various resistance-related proteins and biological factors in cancer cell resistance.

Main Results:

• Experimental strategies, including pharmacological compounds, antibodies, and genetic approaches, have demonstrated the potential to circumvent MDR in vitro and in vivo.
• Clinical application of MDR modulators like verapamil and cyclosporin A has shown some success, particularly in hematological malignancies.
• Treatment of solid tumors with MDR modulators has yielded disappointing results, suggesting that MDR alone does not account for resistance in these cancers.

Conclusions:

• Multidrug resistance (MDR) in cancer is a multifaceted phenomenon involving multiple genetic and protein factors beyond P-glycoprotein.
• While strategies to reverse MDR are promising, their clinical success, especially in solid tumors, is limited by the complex interplay of various resistance mechanisms.
• Further research is needed to address the diverse resistance-related proteins and biological factors (e.g., cell proliferation, vascularization, apoptosis) that contribute to overall cancer resistance.